跳至主要内容
临床试验/NCT06581991
NCT06581991尚未招募不适用

Valine 50mg/ml and Isoleucine 25mg/ml Oral Solutions for Maple Syrup Urine Disease (MSUD) - Acceptability and Tolerance Study

Meta Healthcare Ltd0 个研究点目标入组 5 人开始时间: 2024年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
5
主要终点
Daily data on gastrointestinal tolerance

研究概览

简要总结

This is a prospective, observational research study in 5 children with Maple Syrup Urine Disease (MSUD). Subjects who are currently taking a valine and isoleucine supplement for MSUD will be recruited for a 56 day trial, of a new ready-to-use valine supplement and a new ready-to-use isoleucine supplement, to evaluate the tolerability and acceptability of the study products compared with their usual products.

详细描述

This is a prospective, observational 2-part research study in 5 children with Maple Syrup Urine Disease (MSUD). Subjects who are currently taking a valine and isoleucine supplement for MSUD will be recruited for a 56 day trial, of a new ready-to-use valine supplement (Part 1) and a ready-to-use isoleucine supplement (Part 2), to evaluate the tolerability and acceptability of the study products compared with their usual products.

When an appropriate subject has been identified, they and their parents/ caregivers will be sent a study information sheet via the post. They will be invited to request further information about the study if they wish by contacting the Dietitian. The Dietitian will explain the study in more detail either by telephone or via a face-to-face consultation in a convenient location/preferred venue for the participant and their parent/caregiver. Recruitment of each patient will be by written informed consent, which will be completed by the parents/primary caregivers and taken by the Dietitian. Children will also complete an assent/ consent form. Reimbursement will be offered for any travel expenses incurred for any visits to the hospital that are over and above normal/routine visits.

Subjects will replace their usual daily dose of powdered valine supplement with the equivalent amount of the liquid valine supplement for 28 days (Part 1). They will then return to their usual valine supplement and replace their usual powdered isoleucine supplement with the new liquid isoleucine supplement for a further 28 days (Part 2). The outcome of this assessment will be used in a submission to regulatory authorities to enable the study products to be reimbursable on prescription in the United Kingdom (UK). Subjects will be asked to take the new valine supplement for 28 days (Part 1), then the new isoleucine supplement for 28 days (Part 2). During this time, caregivers will be asked to complete a daily acceptability and tolerance questionnaire recording information on:

  • Usage and adherence
  • Ease of use and any issues with administration
  • Any gastro-intestinal side effects The questions should take a maximum of 10 minutes to complete each day. Additional questions will also be completed at the beginning and end of the study that will consider opinion on both usual valine and isoleucine, and study valine and isoleucine, with respect to taste, appearance, smell, presentation and packaging; ease of administration; how the valine is taken; and any other problems or symptoms.

Weight, height and 3 day dietary intake will also be recorded at the beginning and end of Part 1 and Part 2 of the study. A 3-day food diary will record food/drink intake at the beginning of the study whilst taking their usual supplements (Day -3, -2, -1), for 3 days at the end of Part 1 of the study whilst taking the new valine supplement (Days 26, 27, 28), and for 3 days at the end of Part 2 of the study whilst taking the new isoleucine supplement (Days 54, 55, 56).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Months 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male and female MSUD patients ≥1 year and <16 years of age.
  • Patients diagnosed with MSUD.
  • Taking both valine and isoleucine supplements for MSUD and willing to take the new supplements for 56 days.
  • Absence of comorbidities.
  • Adherence with dietary management and valine and isoleucine supplements.
  • Able to understand and comply with the requirements of the investigation and sign the Informed Consent Form/Assent form

排除标准

  • Age <1 year old and >16 years old.
  • Patients with comorbidities.
  • Any moderate to severe acute illness which in the opinion of the Investigator would interfere with the study procedures or study outcome.
  • History of poor co-operation, non-adherence with dietary management, or poor adherence to investigation procedures.
  • Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

结局指标

主要结局

Daily data on gastrointestinal tolerance

时间窗: From enrollment to end of treatment at 56 days

A daily record of any gastrointestinal symptoms compared with usual valine and isoleucine supplement

Acceptability and tolerance

时间窗: From enrolment to end of treatment at 56

Qualitative questionnaires at study start and end of Part 1 (28 days) and Part 2 (56 dys) of the study

Daily data on study product adherence

时间窗: From enrollment to the end of treatment at 56 days

A daily record of study product intake (actual versus prescribed) to check for adherence

3-day food diaries

时间窗: From enrollment to the end of treatment at 56 days

A record of patient food and fluid intake for 3 days to monitor valine intake from food - at enrollment, end of part 1 and end of part 2

Blood results for valine, leucine, isoleucine

时间窗: From enrollment to end of treatment at 56 days

Routine weekly blood sample taken at home for valine, leucine and isoleucine and posted to the hospital. These will be compared with blood results prior to study commencement to check for any changes

次要结局

  • Weight and height measurement(From enrollment to the end of treatment at 56 days)

研究者

发起方
Meta Healthcare Ltd
申办方类型
Industry
责任方
Sponsor

相似试验